Previous studies have demonstrated that EZH2 inhibitors regulate the NF-κB p65 pathway and influence anti-inflammatory and anti-tumor processes [32,33], but the relevance of EZH2 to the NF-κB pathway has not been investigated in MM. The gene discussed is NFKB1; the disease is Miyoshi myopathy.